Ubs Group Ag Eiger Bio Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

  • $400 Billion
  • Q2 2024

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024
BUY
$0.21 - $0.43 $2,307 - $4,724
10,988 Added 19277.19%
11,045 $2,000
Q3 2023

Nov 09, 2023
BUY
$0.28 - $0.93 $14 - $48
52 Added 1040.0%
57 $0
Q2 2023

Aug 11, 2023
SELL
$0.55 - $1.26 $7,475 - $17,125
-13,592 Reduced 99.96%
5 $0
Q1 2023

May 12, 2023
SELL
$0.89 - $2.52 $2,005 - $5,677
-2,253 Reduced 14.21%
13,597 $12,000
Q4 2022

Feb 08, 2023
BUY
$1.02 - $7.48 $11,171 - $81,920
10,952 Added 223.6%
15,850 $18,000
Q3 2022

Nov 10, 2022
SELL
$6.04 - $9.66 $10,237 - $16,373
-1,695 Reduced 25.71%
4,898 $37,000
Q2 2022

Aug 10, 2022
SELL
$4.99 - $8.96 $33,013 - $59,279
-6,616 Reduced 50.09%
6,593 $42,000
Q1 2022

May 16, 2022
BUY
$3.84 - $9.74 $472 - $1,198
123 Added 0.94%
13,209 $110,000
Q4 2021

Feb 14, 2022
BUY
$5.12 - $8.19 $47,616 - $76,167
9,300 Added 245.64%
13,086 $68,000
Q3 2021

Nov 15, 2021
BUY
$6.68 - $9.1 $9,746 - $13,276
1,459 Added 62.7%
3,786 $25,000
Q2 2021

Aug 13, 2021
SELL
$7.82 - $9.23 $907 - $1,070
-116 Reduced 4.75%
2,327 $20,000
Q1 2021

May 12, 2021
SELL
$8.44 - $12.66 $722,835 - $1.08 Million
-85,644 Reduced 97.23%
2,443 $22,000
Q4 2020

Feb 11, 2021
BUY
$7.98 - $12.29 $67,175 - $103,457
8,418 Added 10.57%
88,087 $1.08 Million
Q3 2020

Nov 12, 2020
SELL
$7.96 - $12.42 $80,523 - $125,640
-10,116 Reduced 11.27%
79,669 $648,000
Q2 2020

Jul 31, 2020
BUY
$5.4 - $13.37 $115,041 - $284,834
21,304 Added 31.11%
89,785 $862,000
Q1 2020

May 01, 2020
BUY
$4.91 - $14.7 $201,997 - $604,758
41,140 Added 150.47%
68,481 $466,000
Q4 2019

Feb 14, 2020
BUY
$9.77 - $15.66 $99,947 - $160,201
10,230 Added 59.79%
27,341 $407,000
Q3 2019

Nov 14, 2019
BUY
$9.59 - $12.0 $159,251 - $199,272
16,606 Added 3288.32%
17,111 $175,000
Q1 2019

May 14, 2019
SELL
$10.31 - $14.38 $16,918 - $23,597
-1,641 Reduced 76.47%
505 $7,000
Q4 2018

Feb 14, 2019
BUY
$8.63 - $12.4 $10,623 - $15,264
1,231 Added 134.54%
2,146 $22,000
Q3 2018

Nov 14, 2018
BUY
$9.6 - $12.9 $3,936 - $5,289
410 Added 81.19%
915 $11,000
Q2 2018

Aug 14, 2018
SELL
$8.3 - $16.8 $9,096 - $18,412
-1,096 Reduced 68.46%
505 $6,000
Q1 2018

May 15, 2018
BUY
$8.1 - $16.0 $664 - $1,312
82 Added 5.4%
1,601 $16,000
Q4 2017

Feb 14, 2018
BUY
$10.5 - $14.15 $15,750 - $21,225
1,500 Added 7894.74%
1,519 $21,000
Q3 2017

Nov 14, 2017
SELL
$7.7 - $11.55 $238 - $358
-31 Reduced 62.0%
19 $0
Q2 2017

Aug 14, 2017
SELL
N/A
-1,526 Reduced 96.83%
50 $0
Q1 2017

Nov 14, 2017
BUY
N/A
1,576
1,576 $18,000

Others Institutions Holding EIGR

# of Institutions
6
Shares Held
748K
Call Options Held
0
Put Options Held
0
View Full List

About Eiger BioPharmaceuticals, Inc.

EIGR Quotes by TradingView
  • Ticker EIGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,966,800
  • Market Cap $418M
  • Description
  • Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...
More about EIGR
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email